Literature DB >> 21741692

Performance of the American Urological Association Symptom Index with and without an additional urge incontinence item.

Michael J Barry1, Andrew L Avins, Sreelatha Meleth.   

Abstract

OBJECTIVE: To examine the value of adding an urge incontinence question to the American Urological Association Symptom Index (AUASI) among men in the Complementary and Alternative Medicine for Urological Symptoms (CAMUS) trial.
METHODS: The CAMUS study was a randomized trial of Saw palmetto fruit extract versus placebo among men aged ≥45 years with an AUASI score of ≥8 and ≤24. The baseline measurements included the AUASI, a question about urge incontinence (UI), the International Prostate Symptom Score quality of life question, and the Benign Prostatic Hyperplasia Impact Index. We correlated the items and scales and examined whether adding the UI question resulted in better prediction of disease-specific health status.
RESULTS: The mean age of the 369 men in the CAMUS trial was 61 years, and mean baseline AUASI score was 14.6. UI was reported infrequently; about 82% of the respondents answered the question "not at all" or "<1 time in 5." UI correlated significantly with all other AUASI items, except for weak stream; the strongest correlation was to urgency (R=0.51, P<.0001). The correlation between the AUASI score and the AUASI+UI score was 0.98 (P<.0001). In a logistic regression analysis predicting the International Prostate Symptom Score quality of life score, adding UI to the AUASI slightly increased the discriminating ability (c statistic increased from 0.77 to 0.78, P<.0001). Similarly, in a linear regression analysis predicting the Benign Prostatic Hyperplasia Impact Index score, adding UI to the AUASI slightly increased the predictive ability (R2 statistic increased from 0.22 to 0.26, P<.0001).
CONCLUSION: According to our analysis in the CAMUS trial population, the value of adding a UI question to the AUASI in terms of predicting bother seemed small at best.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21741692      PMCID: PMC3166397          DOI: 10.1016/j.urology.2011.04.017

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  15 in total

1.  AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations.

Authors: 
Journal:  J Urol       Date:  2003-08       Impact factor: 7.450

Review 2.  Measurement properties of the AUA symptom score: a methodological clarification.

Authors:  K Lawrence
Journal:  Br J Urol       Date:  1996-02

Review 3.  Symptom scores in benign prostatic hyperplasia.

Authors:  M Riehmann; B J Hansen; P V Polishuk; J Nordling; T Hald
Journal:  Urology       Date:  1997-01       Impact factor: 2.649

4.  Comparison of the Danish Prostatic Symptom Score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes. ALFECH Study Group.

Authors:  B J Hansen; S Mortensen; H J Mensink; H Flyger; M Riehmann; N Hendolin; J Nordling; T Hald
Journal:  Br J Urol       Date:  1998-01

5.  Diversity of urinary symptoms in patients tentatively diagnosed with benign prostatic hyperplasia referred to a urologic clinic in Norway.

Authors:  J Haltbakk; B R Hanestad; S Hunskaar
Journal:  Scand J Urol Nephrol       Date:  2004

6.  Distinction between symptoms of voiding and filling in benign prostatic hyperplasia: findings from the Health Professionals Follow-up Study.

Authors:  G Welch; I Kawachi; M J Barry; E Giovannucci; G A Colditz; W C Willett
Journal:  Urology       Date:  1998-03       Impact factor: 2.649

7.  Scoring the short form ICSmaleSF questionnaire. International Continence Society.

Authors:  J L Donovan; T J Peters; P Abrams; S T Brookes; J J de aa Rosette; W Schäfer
Journal:  J Urol       Date:  2000-12       Impact factor: 7.450

8.  Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Authors:  Steven A Kaplan; Claus G Roehrborn; Eric S Rovner; Martin Carlsson; Tamara Bavendam; Zhonghong Guan
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

9.  Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust
Journal:  Med Care       Date:  1995-04       Impact factor: 2.983

10.  Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

Authors:  M J Barry; W O Williford; Y Chang; M Machi; K M Jones; E Walker-Corkery; H Lepor
Journal:  J Urol       Date:  1995-11       Impact factor: 7.450

View more
  3 in total

1.  Treatment status and progression or regression of lower urinary tract symptoms in a general adult population sample.

Authors:  Nancy N Maserejian; Shan Chen; Gretchen R Chiu; Andre B Araujo; Varant Kupelian; Susan A Hall; John B McKinlay
Journal:  J Urol       Date:  2013-07-10       Impact factor: 7.450

2.  Relationships among participant international prostate symptom score, benign prostatic hyperplasia impact index changes and global ratings of change in a trial of phytotherapy in men with lower urinary tract symptoms.

Authors:  Michael J Barry; Alan Cantor; Claus G Roehrborn
Journal:  J Urol       Date:  2012-09-24       Impact factor: 7.450

3.  D-004 ameliorates phenylephrine-induced urodynamic changes and increased prostate and bladder oxidative stress in rats.

Authors:  Ambar Oyarzábal; Yohani Pérez; Vivian Molina; Rosa Mas; Yazmin Ravelo; Sonia Jiménez
Journal:  Transl Androl Urol       Date:  2015-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.